Immunome, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 106.81 million compared to USD 36.9 million a year ago. Basic loss per share from continuing operations was USD 5.38 compared to USD 3.09 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.94 USD | +1.36% | +5.06% | +39.63% |
May. 31 | Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target | MT |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.63% | 896M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.61% | 21.96B | |
-9.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023